Metabolic Dysfunction-Associated Steatohepatitis (MASH): While still in the early stages of research, GLP-1 drugs are being tested for their ability to improve liver function and reduce fibrosis in patients with MASH, a condition often associated with obesity
Specifically, GLP-1 receptor activation decreased anticipatory food reward responses in the OFC, putamen, left insula, and left amygdala, while it increased consummatory reward responses in the right OFC, putamen, left insula, left amygdala, and right caudate (van Bloemendaal et al., 2015a)
Inflammation activity (sum of hepatocyte ballooning and acinary activity) was dichotomized: mild ( 1 points) or severe ( 2 points) activity 51
Phase 2 DXA substudy data showed retatrutide producing greater fat mass reduction without proportionally increased lean mass loss a critical distinction for patients concerned about muscle preservation during aggressive weight loss
The triple-agonist combination filings suggest AstraZeneca is positioning either for a combination-product strategy (a triple agonist co-formulated or co-packaged with an SGLT2 inhibitor, an amylin analog, or a calcitonin/amylin dual like cagrilintide) or for a licensing-target role where the combination claims would apply to partner products
Indians tend to develop type 2 diabetes, cardiovascular disease, and metabolic complications at younger ages than many Western populations
